Skip to main content
Fig. 4 | Biomarker Research

Fig. 4

From: Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives

Fig. 4

Schema for Biomarker-Driven Precision Neoadjuvant Therapy for stage IA2-III NSCLC. The LCMC4 (LEADER) screening trial is an umbrella trial that is designed to detect actionable oncogenic drivers by NGS in patients with resectable, early-stage NSCLC. Patients whose tumors harbor one of these oncogenic drivers are matched to one of the available, effective targeted therapies for patients with metastatic NSCLC. Those patients whose tumors do not harbor actionable driver oncogenes will receive standard of care or investigational neoadjuvant nivolumab and platinum-based chemotherapy

Back to article page

Biomarker Research

ISSN: 2050-7771

Contact us